Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians

Click to increase image sizeClick to decrease image size

Disclosure statement

Dr. Schiller reports grants or contracts for clinical trials from AbbVie, Actininium, Actuate, Arog, Astellas, BMS/Celgene, Celator, Constellation, Daliichi-Sankyo, Deciphera, Delta-Fly, Forma, Fujifilm, Gamida, Genentech-Roche, Geron, Incyte, Karyopharm, Kite/Gilead, Mateon, Onconova, Pfizer, PrECOG, Regimmune, Samus, Sangamo, Sellas, Stemline, Takeda, Agios, Amgen, Jazz, Elevate, Bio, Ono-UK, Novartis, Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amgen, Jazz, Stemline, kite, BMS, Sanofi, Astellas; leadership or fiduciary in other board, society, committee or advocacy group, paid or unpaid from ASH foundation Chair-unpaid; stock or stock options BMS, Amgen, Johnson & Johnson. Dr. Pasquini reports research support from Novartis, Kite, BMS, Amgen (completed 2019), Consultancy (listed as the professional providing insight), BMS (CAR T cell Steering Committee – former as of June 2021). Dr. Chhabra reports institutional research funding from Amgen, Janssen and Sanofi; and honoraria (for advisory boards) from GSK and Sanofi.

Data availability statement

CIBMTR supports accessibility of research in accord with the National Institutes of Health (NIH) Data Sharing Policy and the National Cancer Institute (NCI) Cancer Moonshot Public Access and Data Sharing Policy. The CIBMTR only releases de-identified datasets that comply with all relevant global regulations regarding privacy and confidentiality.

Additional information

Funding

The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research; Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Accenture; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Astellas Pharma US; Bluebird Bio, Inc.; Bristol Myers Squibb Co.; CareDx; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Eurofins Viracor; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd.; Genentech Inc.; Gilead; GlaxoSmithKline; Incyte Corporation; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Magenta Therapeutics; Medac GmbH; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncopeptides, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Tscan; Vertex; Vor Biopharma; Xenikos BV.